Agree bj789..., the SP dive from the breastcancer results to current is questionable.
Biotech holders are usually aware of fluctuations and patience in the science is essential.
Against the trend in our situation though, as one would have thought a rise in SP awaiting AML results.
Thus far, management and current CEO have strategised both models (science and business) flawlessly.
Funds in place till mid to late next year, even with ptx-100 commencement (IMO).
Although gestured by Steve that one doesn’t wait till the tank is empty, hope a premature raise is not his first flaw.
That is, in the interests of the registry and duty of care for long term holders, a raise upon release of positive results (if that be the case) is a more professional and long term initiative on dilution and further investment.
As holders, we wait and see outcomes.
PTX Price at posting:
8.9¢ Sentiment: Hold Disclosure: Held
